AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Watch for long-term issues after gyn. cancer.(EDITORIAL)
Increasingly, the clinical cancer research community is recognizing the importance of unique issues associated with long-term survival following successful treatment of a malignancy. It has been well known for many years that late effects of cancer treatment--such as the development of secondary cancers and heart failure--may result in a devastating outcome.
Investigators have begun to focus, however, on concerns that have a far greater potential impact on the individual patient's overall quality of life than on the duration of survival. Examples of such issues include platinum- or taxane-induced peripheral neuropathy and chemotherapy-associated chronic fatigue that may persist long after the completion of the treatment program.
A report at the annual meeting of the European Society for Therapeutic Radiology and Oncology highlights such concerns specifically in the area of gynecologic cancers. The results of a survey, conducted among a group of 677 women who received radiotherapy for a gynecologic malignancy in Sweden from 1991 to 2003, revealed that "unexpected defecation in clothing" was reported in as many as 10% of respondents. This striking and clearly disturbing result focuses not only on the particular serious issue, but also reveals another problem: the uncertain willingness of cancer patients to report to their health providers what can only be described as very personal and embarrassing concerns.
Recognizing that these women are almost certainly quite happy to be alive (to become a "cancer survivor"), are grateful for the care they have received, and are not particularly interested in being seen as a "complainer" (particularly if it is believed there is little that can be done regarding the problem), it is reasonable to argue that such individuals might remain largely silent about these matters. As a result, the oncology community, both clinicians and researchers, may be quite unaware of the magnitude of this and similar issues--for example, sexual dysfunction.
A patient may ...
- New American Society of Clinical Oncology Report Details Top Advances in...
- News wire article from: AScribe Health News Service December 2, 2005 700+ words
...Roy S. Herbst, MD, PhD, Chair of ASCO's Cancer Communications Committee and Chief of Thoracic Oncology at M.D. Anderson Cancer Center, and Robert J. Mayer, MD, Past Chair ASCO's Cancer Communications Committee and Director of the Center for...
- Research in the area of brain cancer therapy reported from University of Texas,...
- Newspaper article from: Angiogenesis Weekly January 2, 2009 700+ words
...scientists writing in the journal Neuro-Oncology report (see also Brain Cancer Therapy...colleagues, University of Texas, M. D. Anderson Cancer Center. The researchers concluded...Manzano, The University of Texas M D Anderson Cancer Center, Dept. of Neuro-Oncology...
- This Apoptopic Drugs In Oncology Report Focuses Specifically On Breast And...
- Press release article from: M2 Presswire March 25, 2008 700+ words
M2 PRESSWIRE-25 March 2008-Research and Markets: This Apoptopic Drugs In Oncology Report Focuses Specifically On Breast And Prostate Cancer(C)1994-2008 M2 COMMUNICATIONS LTD RDATE:25032008 Dublin - Research and...
- Compare Portfolio And Therapy Focus With Your Peers With Immunotherapy In...
- Press release article from: M2 Presswire May 12, 2008 700+ words
...PRESSWIRE-12 May 2008-Research and Markets: Compare Portfolio And Therapy Focus With Your Peers With Immunotherapy In Oncology Report(C)1994-2008 M2 COMMUNICATIONS LTD RDATE:12052008 Dublin - Research and Markets (http://www.researchandmarkets...
- Research and Markets: Antibodies in Oncology Report Predicts the Commercial...
- Press release article from: Business Wire August 27, 2007 700+ words
DUBLIN, Ireland -- Research and Markets (httpwww.researchandmarkets.com/reports/c66706) has announced the addition of "Antibodies in Oncology: Drug Pipeline Update 2007" to their offering. The commercial and therapeutic success of antibodies like Rituxan, Avastin, and Erbitux will force the
- This Apoptopic Drugs in Oncology Report Focuses Specifically on Breast and...
- Press release article from: Business Wire March 25, 2008 700+ words
DUBLIN, Ireland -- Research and Markets (httpwww.researchandmarkets.com/reports/c86619) has announced the addition of "Triple Analysis: The Drug Target Atlas of Apoptopic Drugs in Oncology and Special Focus on Breast and Prostate Cancer" to their offering. This is the report for professionals
- Scientists at St. George's University, Department of Oncology report research...
- Newspaper article from: Cancer Vaccine Week June 1, 2009 700+ words
A new study, 'The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells,' is now available. "Lenalidomide (Revlimid; CC-5013) and pomalidomide (CC-4047) are IMiDs proprietary drugs having immunomodulatory properties that have both shown
- Researchers from Eberhard-Karls University, Department of Radiation Oncology...
- Newspaper article from: Cancer Gene Therapy Week August 18, 2008 700+ words
Investigators publish new data in the report 'Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair.' According to a study from Germany, "We have already reported that epidermal growth factor receptor/phosphatidylinositol
- Atrophic dermatofibrosarcoma can be tough call.(Cutaneous Oncology)(Report)
- Magazine article from: Skin & Allergy News Dixon, Bruce K. February 1, 2008 700+ words
CHICAGO -- Atrophic dermatofibrosarcoma protuberans is an underrecognized variant that must be treated with wide local excision, Dr. Shari Clarke said at the annual meeting of the American Society for Dermatologic Surgery. Although both wide local excision and Mohs micrographic surgery are
- Researchers from Copenhagen University, Department of Radiation Oncology report...
- Newspaper article from: Blood Weekly September 25, 2008 700+ words
Research findings, 'Risk of developing second cancer from neutron dose in proton therapy as function of field characteristics, organ, and patient age,' are discussed in a new report. In this recent report, researchers in Copenhagen, Denmark conducted a study "To estimate the risk of a second
Source: HighBeam Research, Watch for long-term issues after gyn. cancer.(EDITORIAL)